Anne Nagengast Johnson, Chief Accounting Officer of AtaiBeckley Inc. (NASDAQ:ATAI), filed a Form 4 on September 11, 2026, reporting the disposition of all directly held common stock, stock options, and restricted stock units following the completion of a merger with Eli Lilly and Company.

Key Highlights

  • Full disposition of common stock: Johnson disposed of 140,045 shares of AtaiBeckley common stock on September 11, 2026, leaving a beneficial ownership of 0 shares.
  • Merger consideration: Each share converted into the right to receive $6.75 per share in cash, plus one contingent value right (CVR) representing up to $2.50 in additional cash per CVR upon achievement of specified clinical and regulatory milestones.
  • Seven stock options cancelled: Options covering a combined total of 2,930,951 shares, with exercise prices ranging from $1.18 to $5.68, were cancelled and converted into cash and CVRs; resulting beneficial ownership in each case is 0.
  • Restricted stock units cancelled: 117,000 RSUs were cancelled and converted into the right to receive $6.75 per underlying share in cash, plus one CVR per share.
  • Merger structure: Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged with and into AtaiBeckley Inc. on September 11, 2026, with AtaiBeckley surviving as a wholly owned subsidiary of Eli Lilly.
  • Agreement date: The Agreement and Plan of Merger was dated July 15, 2026, according to the filing.

AtaiBeckley Merger Triggers Full Disposition of Insider Holdings

According to the Form 4 filed on September 11, 2026, all of Anne Nagengast Johnson's direct holdings in AtaiBeckley Inc. were disposed of as a result of the completion of the merger between AtaiBeckley and Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company. The filing discloses that the merger was effected pursuant to an Agreement and Plan of Merger dated July 15, 2026. At the effective time of the merger, Albali Acquisition Corporation merged with and into AtaiBeckley, with AtaiBeckley continuing as a wholly owned subsidiary of Eli Lilly.

The filing states that at the effective time, each share of AtaiBeckley common stock outstanding immediately prior to the closing, subject to certain exceptions, converted into the right to receive $6.75 per share in cash, without interest, plus one CVR per share. The filing describes each CVR as "representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding." Johnson held 140,045 shares of common stock prior to the transaction; post-merger beneficial ownership in common stock is reported as 0.

Seven outstanding stock options with exercise prices of $5.68, $5.54, $2.86, $1.18, $1.84, $1.50, and $3.76, and expiration dates ranging from August 20, 2030 to January 30, 2036, were each cancelled at the effective time. The filing states each option was converted into the right to receive cash equal to the number of underlying shares multiplied by the excess of $6.75 over the applicable exercise price, plus one CVR per underlying share, without regard to vesting. Additionally, 117,000 RSUs were cancelled and converted into the right to receive $6.75 per underlying share in cash, plus one CVR per share, also without regard to vesting. Beneficial ownership in all derivative securities following the transactions is reported as 0.

What Was Disclosed

Anne Nagengast Johnson, Chief Accounting Officer of AtaiBeckley Inc. (NASDAQ:ATAI), disclosed the cancellation and conversion of all directly held common stock, stock options, and RSUs as a result of the September 11, 2026 merger with an Eli Lilly subsidiary, leaving zero remaining beneficial ownership in all securities.